Esperion (ESPR) Gets a Buy Rating from Needham

In a report released today, Serge Belanger from Needham maintained a Buy rating on Esperion (ESPRResearch Report), with a price target of $12.00. The company’s shares closed last Tuesday at $4.18.

According to, Belanger is a 3-star analyst with an average return of 1.5% and a 38.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.

The word on The Street in general, suggests a Hold analyst consensus rating for Esperion with a $12.57 average price target.

See today’s best-performing stocks on TipRanks >>

Esperion’s market cap is currently $117.2M and has a P/E ratio of -0.35.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Read More on ESPR: